Tesla's AI Pivot Faces Profitability Hurdles

The latest Bloomberg Intelligence Podcast delves into the mixed financial signals from major tech and automotive players. The discussion highlights Tesla's recent earnings, which revealed a profit dip despite robust electric vehicle deliveries, potentially complicating Elon Musk's ambitious plans for artificial intelligence and robotics.

Tesla's Shifting Focus and Automotive Realities

Kevin China, Director of Research for the Presidio Group, shared his perspective on Tesla's latest performance. He noted that while Tesla achieved strong delivery volumes, the underlying product mix deteriorated, leading to compressed margins. China questioned whether Tesla is still primarily an automotive company, given its strategic decisions.

The conversation touched on Tesla's long-promised affordable EV, with China suggesting that introducing a lower-cost vehicle would exacerbate current margin pressures, especially with inflating input and production costs. He pointed out that Tesla's move to cease production of models like the Model S and Model X, and its focus on fewer nameplates (Model 3, Y, and Cybertruck), indicates a departure from traditional automaker strategies aimed at broad market segment coverage.

The full discussion can be found on Bloomberg Podcast's YouTube channel.

Automotive Industry's EV Strategy Debate

The podcast also explored the broader automotive industry's approach to electric vehicles. The discussion drew parallels between US automakers pivoting back to profitable trucks and SUVs and deemphasizing their EV businesses, a strategy that could risk them falling behind globally in EV technology. China argued that if profitability is the primary driver, focusing on what makes money is essential, even if it means not going head-to-head with other regions on EV development.

The impact of geopolitical events, like the Iran war, on oil prices and consumer behavior was also considered. The conversation highlighted that consumer choices are often dictated by what manufacturers produce and sell, creating a supply-side push rather than a demand-side pull. The role of government subsidies in driving EV adoption, a strategy prevalent in China but less so in the US, was also discussed, with the observation that automakers naturally gravitate towards profitable ventures.

Google's AI Investment and Capex Surge

The discussion then shifted to the technology sector, focusing on Alphabet Inc. (NASDAQ:GOOGL). Mandep Singh, who leads technology coverage for Bloomberg Intelligence, analyzed Google's recent earnings call. He noted that the conversation was heavily dominated by Google Cloud and TPUs, with surprisingly little focus on the core ad search business.

Singh highlighted Google's significant capital expenditure increases, particularly for AI data center capacity, with projections for 2027 indicating a substantial rise. This surge in spending, even to the point of renting compute from third-party providers, raises questions about investor sentiment and the potential strain on free cash flow. The report indicated that Google experienced negative free cash flow for the quarter, a first-time occurrence, despite strong growth in its cloud business.

Comcast's Strategic Realignment and Media Assets

The podcast also examined the media space, with a focus on Comcast Corporation (NASDAQ:CMCSA). Gita Ranganathan, a media stocks analyst for Bloomberg Intelligence, discussed Comcast's strategy beyond its quarterly results. She noted the company's continued loss of broadband subscribers, a trend driven by competition from telecommunication companies and satellite internet providers like Starlink.

Ranganathan highlighted Comcast's strategic move to separate its media business, NBCUniversal and Sky, into a distinct company. This separation is seen as a way to unlock the value of these media assets, which are performing better than the struggling cable broadband segment. The move is expected to align NBCUniversal's valuation more closely with industry peers like Disney.

Eli Lilly's Weight Loss Drug Advancement

Finally, the conversation turned to the healthcare sector, specifically Eli Lilly and Company (NYSE:LLY). Madison Muller, a healthcare reporter for Bloomberg News, provided an update on Lilly's next-generation weight loss shot, tirzepatide. The drug is on track for regulatory approval filing in the first quarter of 2027, a timeline slightly delayed due to the extensive data required.

Muller explained that tirzepatide combines three gut hormones, potentially offering enhanced weight loss and health benefits compared to existing GLP-1 drugs. The discussion also touched upon the prevalence of compounded versions of these drugs and the ongoing challenges related to insurance coverage, although recent Medicare coverage for certain populations offers a glimmer of hope for increased accessibility.